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Signaling through the Hippo pathway controlsmajor aspects of cell growth and proliferation. Focusing on the
metabolic consequences of Hippo signaling, Mulvihill and colleagues in this issue of Chemistry & Biology
employ a large scale, integrative approach and uncover downstream reorganization of cellular metabolism
when the effector TAZ is upregulated, identifying new connections to lipid metabolism.The ability of cancer cells to undergo per-
petual self-renewal requires alterations in
signal transduction that uncouple cell
proliferation/cell death signals from
external cues as well as metabolic
changes needed to sustain unbridled
growth. How these two aspects of cancer
cells are linked at a biochemical level is a
fundamental unanswered question in
carcinogenesis. In this issue of Chemistry
& Biology, Mulvihill et al. (2014) explore
the impact of TAZ, a coactivator linked
to growth control, on breast cancer with
a specific focus on metabolism.
The Hippo pathway is a highly
conserved signaling pathway that regu-
lates cell number during organ formation
(Cordenonsi et al., 2011). Hippo signaling
has also been implicated in cell over-
growth and cancer phenotypes (Harvey
et al., 2013). Hippo is a serine-threonine
protein kinase that suppresses the tran-
scriptional coactivators TAZ and YAP,
thereby reducing the expression of key
genes involved in cell division and related
processes. In 2011, Cordenonsi and col-
leagues demonstrated that TAZ and YAP
are required to sustain self-renewal and
tumor-initiating capability in breast can-
cer stem cells (Cordenonsi et al., 2011).
Looking at the impact of the Hippo
pathway on cancer metabolism, Mulvihill
et al. (2014) combined proteomics, acti-
vity-based proteomic profiling (ABPP),
and metabolomics approaches to the
metabolic perturbations following TAZ
overexpression in a breast cancer cell
line (MCF10A) and RAS-transformed MII
cells. Cells with constitutively active TAZ
exhibited aggressive features compared
to controls, including higher proliferation,
survival, and migration.
Shotgun proteomic analysis of those
cells confirmed known classic metabolicfeatures of the Warburg effect (Vander
Heiden et al., 2009), including conserved
downregulation of mitochondrial en-
zymes that regulate oxidative meta-
bolism, such as isocitric dehydrogenase
(ICDH), aconitase (ACO2), succinate de-
hydrogenase (SDHA), and pyruvate
dehydrogenase (PDH) and upregulation
of key glycolytic enzymes, such as
enolase1 (ENO1), phosphofrutokinase
(PFKP), glycogen phosphorylase and py-
ruvate kinase (PK), and phosphoglycerate
mutase (PKGM). In fact, the predominant
effect identified by proteomics analysis
was arguably the suppression of mito-
chondrial metabolism, with the upregula-
tion of glycolysis potentially representing
a secondary effect resulting from the
inability of the cells to undertake aerobic
respiration. Untargeted metabolomics
analysis of the TAZ-expressing cells also
confirmed dysregulation in glycolytic and
anaplerosis activities common to tumor
cells and also uncovered significant dys-
regulation in phospholipid metabolism.
The authors also applied a sensitive
ABPP technique to broadly survey the
serine hydrolase class of enzymes altered
by TAZ transduction and/or RAS. Appli-
cation of ABPP allowed the authors
to identify five additional targets, in-
cluding two acetyl hydrolase enzymes,
PAFAH1B2 and PAFAH1B3 that have
not previously been linked to breast can-
cer pathogenesis.
To identify which of the 16 putative
targets uncovered through the ‘‘Omics’’
survey could potentially be relevant in
breast cancer pathogenicity, the authors
silenced the genes individually using
siRNA and then assayed for cell growth.
Using this approach, PAFAH1B2 and
PAFAH1B3 were found to have the great-
est impact. PAFAHs are enzymes thatChemistry & Biology 21, July 17, 2014were previously thought to degrade
platelet activating factor (PAF) signaling
lipids, but are also involved in aspirin
metabolism, inflammation, and anaphy-
laxis (Zhou et al., 2013). The authors
confirmed the dominant role for PAFAH
enzymes in tumorigenesis in two indepen-
dent ways. First, they demonstrated that
stable knockdown of PAFAH1B2 or
PAFAH1B3 significantly reduces prolifer-
ation, survival, migration, invasion, and
growth of highly aggressive breast cancer
cells. Second, they demonstrated that
PAFAH1B3 is elevated in breast tumors
versus normal breast tissue and that
high expression correlates with poor
prognosis.
The mechanism by which PAFAH
modulates the pathogenicity of breast
cancer cells remains unresolved.
Although PAFAH can degrade PAF
signaling lipids in vitro, the intracellular
PAF levels were unaffected in response
to PAFAH knock-down (Mulvihill et al.,
2014). Curiously, the authors found that
PAFAH downregulation was associated
with an increase in lipid intermediates,
including sphingomyelin and the proapo-
ptotic lipid ceramide. The impact of the
TAZ/PAFAH1B3 interaction on sphingoli-
pid metabolite levels is intriguing in light
of a recent study showing that YAP/TAZ
is under the control of the cholesterol
intermediate mevalonate in response to
SREBP upregulation in cancer cells (Sor-
rentino et al., 2014). The impact of sterol
intermediates on TAZ may explain why
statins can sensitize cancer cells to
chemotherapy (Corcos and Le Jossic-
Corcos, 2013). TAZ may function as an
integration point linking cell proliferation
with the metabolism of two major mem-
brane lipids, cholesterol, and sphingo-
myelin, the latter of which can regulateª2014 Elsevier Ltd All rights reserved 803
Chemistry & Biology
Previewscell survival and apoptosis through the
generation of bioactive lipids (Oskouian
and Saba, 2010).
The new findings have several clinical
implications. The authors propose that
PAFAH1B3 may serve as a useful
prognostic marker in newly diagnosed
patients, and, considering that silencing
PAFAH1B3 in breast cancer cells results
in profound growth inhibition, it may
represent a novel therapeutic target for
breast cancer, especially in high risk
patients harboring tumors positive for
TAZ and/or PAFAH1B3. It will be impor-
tant to determine whether inhibiting the
normal activity of PAFAH1B3 is safe
and well tolerated in humans. Whether
PAFAH1B3 will also be a downstream
mediator of YAP/TAZ in other cancers in
which Hippo has been implicated also re-
mains to be determined.
Although promising, the study raises
several important questions that have
not yet been directly addressed. First,
how does the Hippo pathway influence
PAFAH1B3 activity? Second, is the activ-
ity of PAFAH1B3 fundamental to TAZ’s804 Chemistry & Biology 21, July 17, 2014 ª2ability to confer self-renewal capability to
breast cancer cells? Considering a recent
report demonstrating that Hippo regu-
lates the transition from differentiated to
undifferentiated state in liver cells (Yimla-
mai et al., 2014), it seems likely that a
direct impact on the ‘‘stemness’’ of can-
cer stem cells could be mediated by TAZ
targets. Third, what PAFAH substrates/
products mediate tumorigenicity? Last,
this study identified a number of other
genes and proteins that were differentially
expressed or activated in response to
TAZ overexpression in this cancer pro-
gression model. Although not pursued
by the authors, these targets may be rele-
vant in the biology of breast cancer pro-
gression, and thus additional hypotheses
may emerge from this interesting data set.
In conclusion, Mulvihill et al. (2014) pre-
sent exciting work that opens a new
dimension for cancer research and thera-
peutics. Overall, the intriguing results
demonstrate the utility of metabolism-
focused investigations to dissect the
biology of the cancer cell and identify
new targets.014 Elsevier Ltd All rights reservedREFERENCES
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The tandem bromodomains (BD1 and BD2) of the BET family proteins BRD2, BRD3, BRD4, and BRDT are
structurally conserved but not functionally equivalent. In this issue of Chemistry & Biology, Gacias and
colleagues report that a BD1-specific chemical inhibitor, Olinone, enhances oligodendrocyte differentiation,
contrasting the reverse process triggered by broad BD1/BD2-targeting inhibitors, highlighting distinct roles
of BD1 and BD2 in cell fate decision.The amino acid sequences and 3D struc-
tures of the tandem acetyl-lysine (Kac)-
binding bromodomains (BD1 and BD2)
present in the bromodomain and extra-terminal (ET) domain-containing BET
family proteins are evolutionarily con-
served (Wu and Chiang, 2007; Filippako-
poulos et al., 2012). Nevertheless, thefinding of two additional conserved re-
gions with one containing the N-terminal
cluster of casein kinase II phosphoryla-
tion sites (NPS) and one harboring basic
